Monolithic Power Systems (MPWR) Tops Q4 EPS by 25c, Offers Guidance
Get Alerts MPWR Hot Sheet
Price: $1,537.88 -1.65%
Revenue Growth %: +35.6%
Financial Fact:
Basic net income per share (in Dollars per share): 0.35
Today's EPS Names:
OCCI, MAYS, CRMT, More
Revenue Growth %: +35.6%
Financial Fact:
Basic net income per share (in Dollars per share): 0.35
Today's EPS Names:
OCCI, MAYS, CRMT, More
Join SI Premium – FREE
Monolithic Power Systems (NASDAQ: MPWR) reported Q4 EPS of $2.12, $0.25 better than the analyst estimate of $1.87. Revenue for the quarter came in at $336.5 million versus the consensus estimate of $321.29 million.
GUIDANCE:
Monolithic Power Systems sees Q1 2022 revenue of $354-366 million, versus the consensus of $322 million.
- GAAP gross margin between 57.4% and 58.0%. Non-GAAP gross margin (1) between 57.7% and 58.3%, which excludes an estimated impact of stock-based compensation expenses of 0.3%.
- GAAP research and development (“R&D”) and selling, general and administrative (“SG&A”) expenses between $119.2 million and $123.2 million. Non-GAAP R&D and SG&A expenses (1) between $83.4 million and $85.4 million, which excludes estimated stock-based compensation expenses in the range of $35.8 million to $37.8 million.
- Total stock-based compensation expense of $36.9 million to $38.9 million.
- Litigation expense of $2.3 million to $2.7 million.
- Interest income of $1.0 million to $1.4 million.
- Fully diluted shares outstanding between 47.8 million and 48.8 million.
For earnings history and earnings-related data on Monolithic Power Systems (MPWR) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Primoris cuts 2026 outlook on renewables cost overruns, COO exits
- Pfizer lung cancer drug misses survival goal in Phase 3 trial
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share